Mark W. Bondi, Ph.D., ABPP-CN is Professor of Psychiatry at the University of California San Diego and Director of Neuropsychological Assessment Unit at the VA San Diego Healthcare System. He is Board Certified in Clinical Neuropsychology by the American Board of Professional Psychology and is a Fellow of the American Psychological Association and National Academy of Neuropsychology. He has received continuous funding from NIH, VA, and private foundation grants since 1991. His research interests center on the cognitive and brain changes of individuals at risk for dementia. Dr. Bondi has published over 240 articles and book chapters, and he is co-author of the book Mild Cognitive Impairment and Dementia: Definitions, Diagnosis and Treatment. In addition to his research in aging and dementia, he is an active clinician, teacher and supervisor for his institution’s doctoral training, internship, and postdoctoral fellowship programs.

 

Adam M. Brickman, PhD is a Professor in the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain and in the Department of Neurology at Columbia University. Dr. Brickman’s work focuses on understanding the vascular contributions to cognitive aging and Alzheimer’s disease by integrating neuroimaging with observational studies, basic neuroscience, and epidemiological approaches. He is also interested understanding sources of racial and ethnic disparity in Alzheimer’ disease, developing interventions for cognitive aging, and designing neuropsychological instruments to assess cognition in older adults.

Dr. Brickman leads neuroimaging efforts in several large community- and clinic-based studies, such as the Washington Heights Inwood Columbia Aging Project (WHICAP), the WHICAP Offspring Study, and the Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS). He is the Core Leader of the Columbia Alzheimer’s Disease Research Center Biomarker Core.

Dr. Brickman completed his undergraduate studies at Oberlin College, his PhD in neuropsychology at the City University of New York, his internship at Brown Medical School, and his postdoctoral training at Columbia University, where he has been on faculty since 2007.

 

Professor Olivier Godefroy, Neurology Department, Amiens University hospital, Functional Neurosci. Lab., Picardy University Jules Verne. - After a Neurology training in Lille and a PhD thesis on Executive Functions and Stroke, Olivier Godefroy currently works at the Centre Hospitalier Universitaire d'Amiens (where he is leading the Neurology Department) and at the Jules Verne university of Picardy (where he is leading the Functional Neurosciences Lab (EA 4559)). His researches focus on Cognitive Neurology with a special emphasis on Control Executive Functions, Stroke and cortical Neurodegenerative disorders.

 

MD, PhD, Research Director, Institute of Clinical Medicine, University of Eastern Finland

 

HUS Helsinki University Hospital, Neurocenter and University of Helsinki, Faculty of Medicine, Department of Psychology and Logopedics. - Dr. Hanna Jokinen is a specialized neuropsychologist and a senior researcher at the Helsinki University Hospital and University of Helsinki, Finland. She has published scientific papers on vascular cognitive impairment since 2004, runs neuropsychological research within multidisciplinary study projects and participates in several international research collaborations. Dr. Jokinen has focused her work on comprehensive neuropsychological assessment of cognitive symptoms related to cerebrovascular disease, detailed evaluation of domain-specific cognitive impairments (executive dysfunction in particular), early MRI predictors of progressive cognitive decline as well as determinants of functional disability in cerebral small vessel disease.

 

Raj Kalaria is Leader of Neurovascular Research Group in the Translational and Clinical Research Institute, Newcastle University.  He is a Professor of Pathology (Cerebrovascular Diseases) and a neuroepidemiologist.  He qualified from King’s College, University of London and the Royal College of Pathologists.  His interests include the interface between Alzheimer disease (AD) and vascular dementia (VaD), Post-Stroke Dementia and Small Vessel Diseases of the Brain.  He has contributed to consensus criteria for Vascular Cognitive Impairment and leads dementia research projects in indigenous populations of developing countries, particularly sub-Saharan Africa.  Prof Kalaria is a member of the Africa Task Force of the European Academy of Neurology.  He is currently the liaison officer for IBRO-WFN and Chair/President of the International Society for Vascular Behavioural and Cognitive Disorders (VasCog).    

 

Miia Kivipelto, MD, PhD, is Professor in Clinical Geriatrics at Karolinska Institutet (KI), Center for Alzheimer Research and senior geriatrician and Director for Research & Development of Medical Unit Aging at Karolinska University Hospital, Stockholm, Sweden. Part of her Nordic Brain Network multidisciplinary research team (around 100 researchers and clinical staff) is located at University of Eastern Finland and Imperial College London, UK, where she has part time position as Professor. Her frontline research findings have been published in leading journals (330+ publications, H-index 76) and she has received numerous prestigious awards. Dr. Kivipelto’s translational research focuses on the prevention, early diagnosis and treatment of cognitive impairment, dementia and Alzheimer’s disease (AD). Through epidemiological studies, Prof. Kivipelto has identified various lifestyle and vascular risk factors for dementia and interactions with genetic factors and clarified underlying mechanisms. She is the PI of the landmark FINGER trial and founder and scientific leader of World-Wide FINGERS network. Professor Kivipelto is often invited to leading global dementia conferences and task forces.

 

Tuomas Lilius, MD, PhD, is specialist in clinical pharmacology, adjunct professor of pharmacology at University of Helsinki and associate professor at the Center for Translational Neuromedicine, University of Copenhagen. He received his medical degree in 2012 and PhD in 2014 from the University of Helsinki. Dr. Lilius’ research currently focuses on the glymphatic system, a recently recognised fluid flow pathway in the brain that allows the interchange of cerebrospinal fluid and brain interstitial fluid. His previous work has focused on opioid pharmacology, pharmacokinetic interactions of anesthetics and analgesics, and the involvement of neuroinflammation in pain, both in translational and clinical settings.

 

 

Prof Tarja Malm is Professor (tenure track) in Molecular Neurobiology and the head of the Neuroinflammation research group at the A.I.Virtanen Institute, University of Eastern Finland. She obtained her PhD in 2006 in Neurobiology with the focus glial cell biology and carried out her postdoctoral training at the Case Western Reserve University, USA.

Her research focuses on understanding how and why microglia become malfunctional in different neurodegenerative diseases and to elucidate the functional impact of microglia-neuron interactions. Her group uses interdisciplinary approaches and develops novel, human based models to find therapeutic strategies to combat brain diseases. Her research group has pioneered development of methodologies to differentiate microglia and microglia containing cerebral organoids from human induced pluripotent stem cells.

 

Professor Vincent MOK is the Head of Division (Academic Affairs ) of Neurology, Endowed Mok Hing Yiu Professor of Medicine and Assistant Dean of the Faculty of Medicine at the Chinese University of Hong Kong (CUHK).

His research focuses in developing methods that can facilitate early detection of cognitive disorders that are associated with cerebral small vessel disease and Alzheimer’s disease, as well as evaluating novel treatments for such cognitive disorders.

He obtained the Ministry of Education Higher Education Outstanding Scientific Research Output Award (2012), Outstanding Fellow of Faculty of Medicine CUHK (2016) and Excellence Research Award of Hong Kong Food & Health Bureau (2017).

He hosted the 2018 Conference of the International Society of Vascular Behavioural and Cognitive Disorders in Hong Kong.

 

Satu Palva is a Research Director at the Neuroscience Center, Helsinki Institute of Life Science, University of Helsinki, Finland and a Professor of magnetoencephalography (MEG) at the Centre for Cognitive NeuroImaging (CCNi), University of Glasgow, UK. Her research aims at understanding systems-level neuronal basis of cognitive functions and system-level pathologies in brain diseases. Her research focuses on resolving the functional significance of neuronal dynamics and brain functional network interactions in cognitive functions, where she has pioneered the MEG/EEG-based connectomic research. Her multidisciplinary research team uses multimodal neuroimaging  and brain stimulation methods combined with advanced signal processing, network analyses methods and computational modelling.

Professor Leonardo Pantoni, MD, PhD, studied medicine at the University of Florence and graduated in 1989. He was trained in neurology at the School of Neurology of the same university and became certified neurologist in 1993. From August 1993 to July 1995, he held a research fellowship in neuropathology at the Henry Ford Hospital in Detroit, Michigan. In 1999 he received his PhD degree in Neuroscience. From 1998 to 2017, he worked at the Department of Neurological and Psychiatric Sciences of the University of Florence, first as staff neurologist and then as Associate Professor. On November 1, 2017 he became full professor of Neurology at the University of Milan, “Luigi Sacco” Department of Biomedical and Clinical Sciences. He was concurrently appointed director of the Neurology Unit of the Luigi Sacco Hospital. 

His main research areas are dementia and stroke and their variable and complex interconnections. A main research topic is small vessel diseases, either sporadic or genetically transmitted, of which he has explored definitions, radiological and pathological correlates, and therapeutic approaches. He is currently member of the Editorial Boards of Neurology, Stroke, European Stroke Journal, Cerebrovascular Diseases, Acta Neurologica Scandinavica, Cerebral Circulation – Cognition and Behavior, and Neurological Sciences. At a national level, he is president of the Italian Neurogeriatric Society (SINEG). Professor Pantoni has currently over 300 publications indexed in Pubmed and a Hirsh Index (HI) = 69 (source: Scopus).

 

Dr Terry Quinn is Senior Clinical Lecturer and Honorary Consultant, Institute of Cardiovascular and Medical Sciences, University of Glasgow. Terry has a broad research portfolio including trial methodology, functional/cognitive assessment and neuropsychological consequences of stroke. He has published over 150 papers with recent titles in BMJ, JAMA and NEJM. Committee positions include coordinating editor of the Cochrane Dementia Group; chair of the Organisation for Psychological Research in Stroke (OPSYRIS); founder and past chair of the Scottish Care-Home Research Group. He provides expertise on stroke and dementia to the Scottish Parliament and Scottish Intercollegiate Guideline Network. He continues to combine research with teaching and clinical commitments.

 

Pentti Tienari is a chief neurologist at the Helsinki University Hospital and professor of neuroimmunology at the University of Helsinki. He has research experience in epidemiology, genetics, cell biology and immunology of neurological diseases. He started his research activities in the 1990s and defended his PhD thesis “Genetic susceptibility in multiple sclerosis” in 1993. He obtained EMBO postdoctoral fellowship for studies in the University of Heidelberg during 1993-96 (group Konrad Beyreuther). These studies unraveled axonal sorting signals of amyloid precursor protein and identified a novel pathway for the generation of intraneuronal amyloid-beta peptide. He established his own research group in 1996 and is currently studying both neuroinflammatory and neurodegenerative diseases. His group played an important role in the discovery of the C9ORF72 mutation in ALS and frontotemporal dementia and is currently continuing genetic studies of ALS and studying the mechanistic role of somatic mutations in multiple sclerosis and other nervous system diseases.

 

Research group leader, professor, specialist in neurology and psychiatry, and chairman of the Swedish Association of Cognitive Medicine. Affiliation: University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden. About 500 articles in the field of cognitive disorders and dementia. Main topics: Alzheimer’s disease, vascular dementia of the small vessel type, cerebrospinal fluid biomarkers, imaging analysis, cognitive neuropsychology diagnosis and classification. Since 2020 editor-in-chief of the Vas-Cog journal Cerebral Circulation Cognition and Behaviour.

 

Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg and leads the UK DRI Fluid Biomarker Laboratory at UCL. His main research focus and clinical interest are fluid biomarkers for central nervous system diseases, Alzheimer’s disease in particular. He has published more than 1100 papers and has received numerous awards.